Name
Blastic plasmacytoid dendritic cell neoplasm
ICD-O-2 Morphology
9865/3: FAB M2, NOS; Acute myelocytic leukemia with maturation
ICD-O-3 Morphology
Effective
2001 and later
Reportable
for cases diagnosed
2001 and later
Primary Site(s)
See Module 4: Rules PH7, PH8
Most common sites of involvement: skin, bone marrow, peripheral blood, and lymph nodes
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Rare type of hematopoietic neoplasm.
Bone marrow involvement can be minimal at presentation but invariably develops with progression of disease.
Following initial response to chemotherapy, relapses invariably occur involving skin alone or associated with other sites including soft tissue and the central nervous system.
Bone marrow involvement can be minimal at presentation but invariably develops with progression of disease.
Following initial response to chemotherapy, relapses invariably occur involving skin alone or associated with other sites including soft tissue and the central nervous system.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
Module 4: PH7, PH8
Alternate Names
Agranular CD4+ natural killer cell leukemia
Agranular CD4+ NK leukemia [OBS]
Agranular CD4+ CD56+ hematodermic neoplasm/tumor
BPDC
LBL
Lymphoblastoma [OBS]
Definition
Blastic plasmacytoid dendritic cell neoplasm is a clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells (PDCs, also called professional type 1 interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination.
Definitive Diagnostic Methods
Bone marrow biopsy
Genetic testing
Histologic confirmation
Immunophenotyping
Genetics Data
Immunophenotyping
CD2AP+ (expression/positive)
CD4+ (expression/positive)
CD7
CD33
CD43+ (expression/positive)
CD45RA+ (expression/positive)
CD56+ (expression/positive)
CD123 (IL3)+ (expression/positive)
CD303+ (expression/positive)
SPIB+ (expression/positive)
TCF4+ (expression/positive)
TCL1A+ (expression/positive)
Type I interferon-dependent molecule MX1 expression
Treatments
Chemotherapy
Transformations to
There are no known transformations
Transformations from
There are no known transformations
Same Primaries
Corresponding ICD-9 Codes
202.8 Other lymphoma
Corresponding ICD-10 Codes
C85.7 Other specified types of non-Hodgkin lymphoma
Corresponding ICD-10-CM Codes (U.S. only)
C86.4 Blastic NK-cell lymphoma (effective October 01, 2015)
Signs and Symptoms
Easy bruising or bleeding
Fatigue
Fever
Petechiae
Shortness of breath
Weakness
Weight loss or loss of appetite
Diagnostic Exams
Progression and Transformation
80-90% of patients show positive response to chemotherapy, but many releapse with subsequent resistance to drugs
Long lasting remission seen in sporadic cases
Epidemiology and Mortality
Age: 61-67 years median age (occurs in children and adults)
Incidence: rare
Sex: male predominance
Survival: 12-14 months median survival
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Blastic plasmacytoid dendritic cell neoplasm
Pages: 174-177
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Blastic plasmacytoid dendritic cell neoplasm
Pages: 174-177
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577